 "Wockhardt hits 52-week low")
Wockhardt has fallen to its 52-week low of Rs 683, down 1.4% on the BSE in intra-day trade.
The stock down 16% in past seven trading sessions after the pharmaceutical company reported a disappointing set of numbers for the quarter ended September 30, 2016 (Q2FY17). On comparison, the S&P BSE Sensex and S&P BSE Healthcare index were down 6% and 3.9%, respectively.
Wockhardt had reported a sharp 82% year on year (YoY) drop in consolidated net profit at Rs 17.02 crore in Q2FY17 as compared to Rs 92.45 crore in the year ago quarter.
Total income from operations declined 13% at Rs 1,065 crore in YoY basis.
"EBITDA (earnings before interest, taxes, depreciation and amortization) margin stood at 9.4% in Q2FY17 from 16.2% in Q2FY16," Wockhardt said in a statement.
At 02:07 pm, the stock was down less than 1% and trading at Rs 689 on BSE as compared to 0.24% rise in the benchmark index. A combined 715,435 shares changed hands on the counter on BSE and NSE so far.
The stock down 16% in past seven trading sessions after the pharmaceutical company reported a disappointing set of numbers for the quarter ended September 30, 2016 (Q2FY17). On comparison, the S&P BSE Sensex and S&P BSE Healthcare index were down 6% and 3.9%, respectively.
Wockhardt had reported a sharp 82% year on year (YoY) drop in consolidated net profit at Rs 17.02 crore in Q2FY17 as compared to Rs 92.45 crore in the year ago quarter.
Total income from operations declined 13% at Rs 1,065 crore in YoY basis.
"EBITDA (earnings before interest, taxes, depreciation and amortization) margin stood at 9.4% in Q2FY17 from 16.2% in Q2FY16," Wockhardt said in a statement.
At 02:07 pm, the stock was down less than 1% and trading at Rs 689 on BSE as compared to 0.24% rise in the benchmark index. A combined 715,435 shares changed hands on the counter on BSE and NSE so far.